How to Read This Tracker
Three different things get lumped together when people ask if a peptide is "legal": whether it's an FDA-approved drug, whether it's eligible for a licensed pharmacy to legally compound under Section 503A, and whether it's simply available to buy labeled for research use only. Those are three separate regulatory questions, and this tracker keeps them separate rather than collapsing them into a single yes-or-no answer. See What Is FDA's 503A Bulks List? and What Is a Compounded Peptide? for background on how those categories actually work.
Status Tracker
| Compound | FDA-Approved Drug? | 503A Compounding Status | Last Reviewed |
|---|---|---|---|
| BPC-157 | No | Rx compounding allowed under draft HHS policy (Oct 2026) | Oct 29, 2026 |
| TB-500 | No | Rx compounding allowed under draft HHS policy (Oct 2026) | Oct 29, 2026 |
| MOTS-c | No | Rx compounding allowed under draft HHS policy (Oct 2026) | Oct 29, 2026 |
| KPV | No | Rx compounding allowed under draft HHS policy (Oct 2026) | Oct 29, 2026 |
| Semax | No | Rx compounding allowed under draft HHS policy (Oct 2026) | Oct 29, 2026 |
| Epithalon | No | Rx compounding allowed under draft HHS policy (Oct 2026) | Oct 29, 2026 |
| DSIP (Emideltide) | No | PCAC did not recommend, Jul 2026 | Oct 29, 2026 |
| CJC-1295 | No | Not part of Jul 2026 review | Oct 29, 2026 |
| Ipamorelin | No | Not part of Jul 2026 review | Oct 29, 2026 |
| Sermorelin | Formerly, as Geref | Not part of Jul 2026 review | Oct 29, 2026 |
| Selank | No | Not part of Jul 2026 review | Oct 29, 2026 |
The October 2026 HHS Draft Policy
On October 28, 2026, the U.S. Department of Health and Human Services announced a draft enforcement discretion policy for 503A compounding using six peptide bulk drug substances. HHS published it in the Federal Register on October 30, 2026 (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496). It was published as a draft: it is nonbinding, HHS can revise or withdraw it, and public comments are open for two weeks after publication, until about November 13, 2026. In plain terms, HHS says it does not intend to take action against licensed 503A pharmacies that compound these six peptides for individual patients, as long as they meet the policy's conditions, while FDA completes rulemaking on the 503A Bulks List (Frier Levitt summary).
| Peptide | Routes covered by the policy |
|---|---|
| BPC-157 (acetate) | Subcutaneous, intramuscular, oral, topical |
| TB-500 (acetate) | Subcutaneous, intramuscular |
| Epitalon (acetate) | Subcutaneous, intramuscular, in intermittent courses |
| Semax (free base) | Intranasal |
| KPV (acetate) | Topical, oral |
| MOTS-c (acetate) | Subcutaneous, intramuscular |
Conditions. Each compounded product may contain only one of these ingredients, so blends such as BPC-157 with TB-500 are not covered. The ingredient must come from an FDA-registered manufacturer that follows current good manufacturing practice, with the manufacturing facility listed on the certificate of analysis. It must be fully tested for identity, purity, potency, impurities and contaminants, including bacterial endotoxins. Products must be patient-specific, carry the statement "This is a compounded drug product. Not for resale.", and serious adverse events must be reported through FDA's MedWatch program. The policy also sets conditions on documenting how well oral products are absorbed and on which delivery devices can be packaged with a product.
What it does not do. It does not approve these peptides, add them to the 503A Bulks List, cover 503B outsourcing facilities, or make research use only products legal for human use. It is non-binding, does not override state pharmacy board rules, and HHS can revise or withdraw it if safety or quality concerns arise. Formal rulemaking is expected to take roughly 12 to 24 months.
Still Pending
- No proposed rule yet. As of October 30, 2026, FDA has not published a proposed or final rule acting on the July 2026 PCAC recommendations, and the 503A Bulks List in 21 CFR 216.23 is unchanged.
- Next PCAC review. FDA says the committee will meet before the end of February 2027 to discuss LL-37 (cathelicidin), GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF for the 503A Bulks List (FDA committee page). None of those five is covered by the draft policy.
What "No FDA-Approved Drug" Actually Means
For every compound on this tracker except Sermorelin's discontinued past approval, "No FDA-Approved Drug" means the compound has not gone through the FDA's clinical trial process for safety and effectiveness in the way a prescription medication has. It does not by itself mean the compound is illegal to sell or possess. Most of these peptides are currently sold labeled for research use only, a separate category covered in What Does "Research Use Only" Actually Mean?.
What Would Change a Row on This Tracker
A row would change if the FDA formally adds a substance to the 503A Bulks List through notice-and-comment rulemaking, if HHS revises or withdraws its October 2026 draft compounding policy, if a compound receives its own FDA drug approval through a sponsor's clinical trial program, or if a significant enforcement action or public FDA statement changes the practical regulatory picture. Routine research publications, by themselves, do not change regulatory status and are covered separately in BioStackIQ's Evidence Reviews cluster.
Related Reading
For the story behind the six compounds' July 2026 PCAC recommendation, see What Changed With BPC-157, TB-500 and MOTS-c in 2026?. For the broader legal picture around buying and using research peptides, see Are Peptides Legal in the United States? 2026 Guide and FDA-Approved Peptides vs Research Peptides.
Frequently Asked Questions
Are any of the peptides on this tracker FDA-approved drugs?
Sermorelin has a past FDA drug-approval history as Geref, though it was discontinued commercially and current research-chemical Sermorelin is not regulated the way that approved drug was. None of the other 10 compounds on this tracker is or has ever been an FDA-approved drug.
What does it mean that a peptide is 'on the 503A Bulks List'?
Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacies to compound medications for individual patients under certain conditions. A substance generally has to be on the 503A Bulks List, have its own U.S. Pharmacopoeia monograph, or be a component of an FDA-approved drug before it can legally be compounded this way. As of this tracker's last review, none of the peptides discussed here are on that list. Separately, a draft HHS policy announced October 28, 2026 lets licensed 503A pharmacies compound six of them by prescription under strict conditions while FDA completes rulemaking.
How often is this tracker updated?
This tracker is reviewed whenever there's a meaningful regulatory development, such as an FDA advisory committee vote, a Federal Register notice, or a final rule, and at minimum whenever BioStackIQ's other regulatory content is reviewed. Each row shows a last-reviewed date so you can see how current the information is.
Does a peptide being 'research use only' mean it's illegal?
Not automatically. Selling a substance labeled for research use only, and not for human consumption, is a distinct regulatory category from an approved drug or a legally compoundable substance. It generally means the seller isn't making a drug claim, not that possession is illegal, though how it's marketed and used can still raise separate legal questions. This is a general explanation, not legal advice for any specific situation.
Has the FDA added any peptides to the 503A Bulks List since the July 2026 vote?
No. As of October 30, 2026, FDA has not published a proposed or final rule acting on the July 2026 PCAC recommendations, and none of the peptides on this tracker is on the 503A Bulks List. The draft HHS policy announced October 28, 2026 allows prescription compounding of six of them in the meantime, but that is not the same as being added to the list.
What is the October 2026 HHS draft policy for compounding peptides?
On October 28, 2026, HHS announced a draft enforcement discretion policy that lets licensed 503A pharmacies compound six peptides, BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c, for individual patients with a prescription. It requires a single ingredient from an FDA-registered, CGMP-compliant manufacturer, full testing, specific routes of use, a compounded drug label and adverse event reporting. It does not cover 503B outsourcing facilities or research chemical sellers, it is not FDA approval, and it applies while FDA completes rulemaking on the 503A Bulks List.
Which peptides will the FDA advisory committee review next?
FDA says its Pharmacy Compounding Advisory Committee will meet before the end of February 2027 to discuss LL-37 (cathelicidin), GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF for the 503A Bulks List. No exact date had been announced as of late October 2026.